Hyderabad-based Pulse Prescription drugs has obtained regulatory approval from the Medication Controller Basic of India (DCGI) for its Nano-Service Entrapped Vitamin D3 Oral Dispersion, shifting the corporate’s nanomedicine analysis right into a regulated product class.
The approval pertains to a formulation designed to enhance the supply of Vitamin D3, a fat-soluble nutrient that may current challenges in standard formulations. The corporate mentioned medical research of the formulation confirmed serum Vitamin D ranges that have been 50–60 per cent greater than these noticed with standard formulations.
Nanotechnology Strikes Towards Scientific Use
Pulse Prescription drugs has been engaged on nanotechnology-based drug supply since 2010, specializing in formulations for compounds with limitations in standard supply techniques. Its Aqueol platform is designed to disperse lipophilic compounds in water-based mediums. The corporate says the platform has been utilized in creating formulations supposed to enhance bioavailability and supply traits.
The most recent regulatory approval might have wider implications for the corporate’s nanomedicine pipeline, which incorporates work on different vitamins equivalent to Vitamin K2-7, Vitamin B12 and iron, in addition to generally used medicines together with paracetamol, diclofenac and ibuprofen. Nonetheless, the industrial and medical relevance of those formulations will depend upon regulatory clearances, manufacturing capabilities, market adoption and proof generated for particular person merchandise.
Pulse additionally has an mental property portfolio round its drug-delivery applied sciences. The corporate at the moment holds 5 granted patents throughout India, the US, Russia, Mexico and Australia, whereas an EU patent associated to its Aqueol expertise is within the closing phases of approval, in response to the corporate. It has additionally filed patents for 4 different proprietary platforms throughout seven nations and is engaged on further filings.
The corporate is trying to broaden its industrial operations throughout South-East Asia, Africa, the Center East, Russia-CIS and Latin America, whereas exploring collaborations within the US and Europe. Okay. V. Rambabu, Founder and Managing Director, Pulse Prescription drugs, mentioned the corporate’s focus has been on addressing limitations in drug supply somewhat than pursuing nanotechnology as an finish in itself.
“For us, nanotechnology has by no means been about expertise for expertise’s sake. Our goal has all the time been to determine necessary unmet wants in drug supply and develop sensible options that may make a significant distinction to sufferers,” he mentioned. He added that India’s pharmaceutical business might more and more contribute to drug-delivery innovation alongside its established position in generic medicines.
The DCGI approval represents a regulatory milestone for Pulse Prescription drugs, whereas the corporate’s broader pipeline will decide how its nanotechnology platforms translate into commercially obtainable merchandise and wider medical purposes.
